Contrast developer Advanced Magnetics has begun phase II trials of its lead development product, Code 7228, for MR angiography. The trial’s principal investigator will be Dr. Martin Prince of Weill Cornell Medical College and the New York Weill Cornell Medical Center of New York-Presbyterian Hospital, according to the firm.
Code 7228 is a coated iron oxide agent that the Cambridge, MA-based firm believes holds promise in cardiovascular imaging applications such as MRA, owing to its safety profile and blood pool persistence.
By AuntMinnie.com staff writers
January 24, 2001
Related Reading
Advanced Magnetics trims net loss in Q1, January 19, 2001
Copyright © 2001 AuntMinnie.com
